Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (NVUC).

Weyerer V, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Compérat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S.

Histopathology. 2019 Jul 26. doi: 10.1111/his.13958. [Epub ahead of print]

PMID:
31348552
2.

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).

Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R.

Oncologist. 2019 Jul 10. pii: theoncologist.2018-0280. doi: 10.1634/theoncologist.2018-0280. [Epub ahead of print]

PMID:
31292267
3.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
4.

No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.

Stoehr R, Wendler O, Giedl J, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Bertz S, Hartmann A.

Pathobiology. 2019;86(2-3):145-151. doi: 10.1159/000495251. Epub 2019 Jan 16.

PMID:
30650417
5.

A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.

Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M, Lehmann J, Wunderlich H, Grimm MO, Stöckle M, Junker K.

J Cancer Res Clin Oncol. 2019 Apr;145(4):811-820. doi: 10.1007/s00432-018-02829-4. Epub 2019 Jan 2.

PMID:
30603903
6.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
7.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

8.

Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S.

Hum Pathol. 2018 Oct;80:55-64. doi: 10.1016/j.humpath.2018.05.022. Epub 2018 Jun 6.

9.

DICER1 mutation-positive giant botryoid fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma.

Eckstein M, Agaimy A, Woenckhaus J, Winter A, Bittmann I, Janzen J, Bertz S, Haller F, Hartmann A.

Hum Pathol. 2019 Feb;84:1-7. doi: 10.1016/j.humpath.2018.05.015. Epub 2018 Jun 5.

PMID:
29883781
10.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
11.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
12.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
13.

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A.

Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22.

14.

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma.

Bellut J, Bertz S, Nolte E, Stöhr C, Polifka I, Lieb V, Herrmann E, Jung R, Hartmann A, Wullich B, Taubert H, Wach S.

Sci Rep. 2017 Nov 27;7(1):16424. doi: 10.1038/s41598-017-16144-4.

15.

Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A.

Leuk Lymphoma. 2018 May;59(5):1260-1263. doi: 10.1080/10428194.2017.1370546. Epub 2017 Sep 3. No abstract available.

PMID:
28868954
16.

Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases.

Compérat E, McKenney JK, Hartmann A, Hes O, Bertz S, Varinot J, Brimo F.

Histopathology. 2017 Nov;71(5):703-710. doi: 10.1111/his.13280. Epub 2017 Aug 14.

PMID:
28805264
17.

[Primary mixed adeno-neuroendocrine carcinoma (MANEC) of the urinary bladder: a rare entity].

Eckstein M, Rasper B, Busche J, Stachetzki U, Wistuba DE, Agaimy A, Hartmann A, Bertz S.

Aktuelle Urol. 2017 Aug;48(4):350-355. doi: 10.1055/s-0043-110088. Epub 2017 May 31. German.

PMID:
28564709
18.

Fever of unknown origin, giant cell arteritis, and aortic dissection.

Hofheinz K, Bertz S, Wacker J, Schett G, Manger B.

Z Rheumatol. 2017 Feb;76(1):83-86. doi: 10.1007/s00393-016-0245-5.

PMID:
28074266
19.

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Otto W, Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A.

Int Urol Nephrol. 2017 Mar;49(3):431-437. doi: 10.1007/s11255-016-1491-9. Epub 2016 Dec 29.

PMID:
28035618
20.

Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, Keck B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):339-44. doi: 10.1007/s00428-016-1986-x. Epub 2016 Jul 8.

PMID:
27392930
21.

Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.

Agaimy A, Bertz S, Cheng L, Hes O, Junker K, Keck B, Lopez-Beltran A, Stöckle M, Wullich B, Hartmann A.

Virchows Arch. 2016 Sep;469(3):321-30. doi: 10.1007/s00428-016-1977-y. Epub 2016 Jun 23.

PMID:
27339451
22.

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.

Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S.

Oncogenesis. 2016 Feb 29;5:e205. doi: 10.1038/oncsis.2016.15.

23.

[Specific types of bladder cancer].

Bertz S, Hartmann A, Knüchel-Clarke R, Gaisa NT.

Pathologe. 2016 Feb;37(1):40-51. doi: 10.1007/s00292-015-0129-5. German.

PMID:
26782034
24.

A Multiplex Kindred with Hennekam Syndrome due to Homozygosity for a CCBE1 Mutation that does not Prevent Protein Expression.

Jackson CC, Best L, Lorenzo L, Casanova JL, Wacker J, Bertz S, Agaimy A, Harrer T.

J Clin Immunol. 2016 Jan;36(1):19-27. doi: 10.1007/s10875-015-0225-6. Epub 2015 Dec 19.

25.

Mesothelial/monocytic incidental cardiac excrescences (cardiac MICE) associated with acute aortic dissection: a study of two cases.

Strecker T, Bertz S, Wachter DL, Weyand M, Agaimy A.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):3850-6. eCollection 2015.

26.

[Anamnesis, Pathological Assessment, Therapeutic Features and Course of Disease: Retrospective Study on Clinical-Based Factors for Prediction of Cancer-Specific Survival of 378 Patients with Stage pT1 Urothelial Bladder Carcinoma].

Breyer J, Otto W, Hartmann A, Bumes B, Bründl J, Gierth M, Bertz S, Denzinger S, Burger M, Lausenmeyer EM.

Aktuelle Urol. 2015 May;46(3):221-6. doi: 10.1055/s-0035-1549905. Epub 2015 Jun 12. German.

PMID:
26077306
27.

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.

Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A.

Mol Med. 2015 May 13;21:371-80. doi: 10.2119/molmed.2014.00250.

28.

Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.

Bertz S, Abeé C, Schwarz-Furlan S, Alfer J, Hofstädter F, Stoehr R, Hartmann A, Gaumann AK.

Virchows Arch. 2014 Dec;465(6):687-95. doi: 10.1007/s00428-014-1672-9. Epub 2014 Oct 19.

PMID:
25326864
29.

Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.

Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.

Int J Cancer. 2015 Jan 15;136(2):443-51. doi: 10.1002/ijc.28987. Epub 2014 Jun 12.

30.

[Prognostic and predictive molecular markers for urologic cancers].

Hartmann A, Schlomm T, Bertz S, Heinzelmann J, Hölters S, Simon R, Stoehr R, Junker K.

Urologe A. 2014 Apr;53(4):491-500. doi: 10.1007/s00120-014-3442-3. Review. German.

PMID:
24700189
31.

Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.

Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, Catto JW.

Clin Cancer Res. 2014 Apr 1;20(7):1990-2000. doi: 10.1158/1078-0432.CCR-13-2805. Epub 2014 Feb 10.

32.

Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.

Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E.

Carcinogenesis. 2014 Mar;35(3):727-36. doi: 10.1093/carcin/bgt375. Epub 2013 Nov 21.

PMID:
24265292
33.

The X-ray crystal structure of a cuprate-carbonyl π-complex.

Bertz SH, Hardin RA, Heavey TJ, Ogle CA.

Angew Chem Int Ed Engl. 2013 Sep 23;52(39):10250-2. doi: 10.1002/anie.201303783. Epub 2013 Aug 13. No abstract available.

PMID:
23943548
34.

Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.

Otto W, Denzinger S, Fritsche HM, Burger M, Rößler W, Bertz S, May M, Hartmann A, Hofstädter F, Wieland WF, Eder F.

Clin Genitourin Cancer. 2013 Dec;11(4):537-44. doi: 10.1016/j.clgc.2013.05.001. Epub 2013 Jul 10.

PMID:
23850551
35.

SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.

Keck B, Wach S, Goebell PJ, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A.

Ann Surg Oncol. 2013 Oct;20(11):3669-74. doi: 10.1245/s10434-013-3075-6. Epub 2013 Jun 27.

PMID:
23807662
36.

First X-ray crystal structure and internal reference diffusion-ordered NMR spectroscopy study of the prototypical Posner reagent, MeCu(SPh)Li(THF)3.

Bertz SH, Hardin RA, Heavey TJ, Jones DS, Monroe TB, Murphy MD, Ogle CA, Whaley TN.

Chemistry. 2013 Jul 29;19(31):10138-41. doi: 10.1002/chem.201301415. Epub 2013 Jun 18.

PMID:
23780906
37.

Aldehydes and ketones form intermediate π complexes with the Gilman reagent, Me2CuLi, at low temperatures in tetrahydrofuran.

Bertz SH, Hardin RA, Ogle CA.

J Am Chem Soc. 2013 Jul 3;135(26):9656-8. doi: 10.1021/ja404105u. Epub 2013 Jun 18.

PMID:
23777294
38.

Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes.

Stoehr CG, Buettner-Herold M, Kamphausen E, Bertz S, Hartmann A, Seliger B.

Int J Clin Exp Pathol. 2013 May 15;6(6):998-1008. Print 2013.

39.

Is gender becoming relevant in uro-oncological research? A bibliographical analysis.

Kunath F, Keck B, Bertz S, Brookman-May S, May M, Vergho D, Hartmann A, Riedmiller H, Wullich B, Burger M.

World J Urol. 2013 Oct;31(5):1065-72. doi: 10.1007/s00345-013-1069-4. Epub 2013 Apr 9. Review.

PMID:
23568444
40.

π-Complexes from acyl cyanides and lithium dimethylcuprate(I).

Bertz SH, Hardin RA, Murphy MD, Ogle CA.

Chem Commun (Camb). 2013 Apr 14;49(29):3010-2. doi: 10.1039/c3cc40602d.

PMID:
23459603
41.

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.

Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A.

BMC Cancer. 2013 Feb 8;13:71. doi: 10.1186/1471-2407-13-71.

42.

Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder.

Keck B, Wach S, Kunath F, Bertz S, Taubert H, Lehmann J, Stöckle M, Wullich B, Hartmann A.

Ann Surg Oncol. 2013 Jul;20(7):2440-5. doi: 10.1245/s10434-012-2709-4. Epub 2012 Oct 30.

PMID:
23108554
43.

Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.

Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup N, Schepeler T, Ulhøi BP, Agerbaek M, Hartmann A, Bertz S, Wittlinger M, Fietkau R, Rödel C, Borre M, Jensen JB, Orntoft T, Dyrskjøt L.

BJU Int. 2012 Dec;110(11 Pt C):E1228-36. doi: 10.1111/j.1464-410X.2012.11564.x. Epub 2012 Oct 9.

44.

[Intraoperative frozen section diagnosis of the genitourinary tract].

Bertz S, Schmitz-Dräger BJ, Protzel C, Hartmann A.

Pathologe. 2012 Sep;33(5):441-9. doi: 10.1007/s00292-012-1600-1. Review. German.

PMID:
22892659
45.

Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.

Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stöhr R, Link S, Hofstädter F, Hartmann A.

Eur Urol. 2014 Jan;65(1):218-26. doi: 10.1016/j.eururo.2012.05.033. Epub 2012 May 19.

PMID:
22633802
46.

Rapid injection NMR reveals η3 'π-allyl' Cu(III) intermediates in addition reactions of organocuprate reagents.

Bertz SH, Hardin RA, Murphy MD, Ogle CA, Richter JD, Thomas AA.

J Am Chem Soc. 2012 Jun 13;134(23):9557-60. doi: 10.1021/ja3022363. Epub 2012 May 25.

PMID:
22631600
47.

Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma.

Stoehr C, Burger M, Stoehr R, Bertz S, Ruemmele P, Hofstaedter F, Denzinger S, Wieland WF, Hartmann A, Walter B.

Pathobiology. 2012;79(3):162-8. doi: 10.1159/000335642. Epub 2012 Feb 22.

48.

Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.

Walter B, Hartmann A, Hofstädter F, Junker K, Moch H, Bertz S, Denzinger S, Otto W, Gajda M, Stoehr CG.

Virchows Arch. 2012 Mar;460(3):343-52. doi: 10.1007/s00428-011-1187-6. Epub 2012 Feb 17.

PMID:
22350003
49.

Minimization of organocuprate complexity through self-organization: remarkable orientation effect in mixed cuprate π complexes.

Bertz SH, Hardin RA, Murphy MD, Ogle CA, Richter JD, Thomas AA.

Angew Chem Int Ed Engl. 2012 Mar 12;51(11):2681-5. doi: 10.1002/anie.201107060. Epub 2012 Feb 1.

PMID:
22298492
50.

Base-mediated stereospecific synthesis of aryloxy and amino substituted ethyl acrylates.

Kabir MS, Namjoshi OA, Verma R, Lorenz M, Tiruveedhula VV, Monte A, Bertz SH, Schwabacher AW, Cook JM.

J Org Chem. 2012 Jan 6;77(1):300-10. doi: 10.1021/jo201948e. Epub 2011 Nov 28.

Supplemental Content

Support Center